A 90-day review delivers the bad news in one hit, and the CSL Vifor write-down is the line investors will fixate on.
CSL Limited (ASX:CSL) has done what new leadership at troubled blue chips usually does. Interim CEO Gordon Naylor used his 90-day review to clear the decks, cut FY26 guidance and flag roughly US$5 billion in additional non-cash pre-tax impairments across FY26 and FY27.
Revenue for FY26 is now expected to land around US$15.2 billion on a constant currency basis, with NPATA of about US$3.1 billion before restructuring and impairment costs. The cut is driven by three things, a US$300 million hit from normalising channel inventory in US immunoglobulin, a US$200 million revenue drag from lower albumin prices in China, and another US$150 million from the Middle East conflict, HEMGENIX growth and competition in iron.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
The bigger story sits underneath the guidance change. The flagged impairments include CSL Vifor intangibles, the very acquisition that has hung over the share price for two years. Naylor is effectively conceding the deal did not deliver.
The CSL Vifor write-down is the real headline
Of the US$5 billion in flagged impairments, the CSL Vifor product portfolio is the line that matters most. CSL paid roughly US$11.7 billion for Vifor in 2022 to diversify beyond plasma into iron and nephrology. Today’s announcement confirms what the share price has been signalling for some time.
Management lists Vifor among the historical investment cases that did not eventuate, alongside infrastructure overbuild and invested capital growing faster than earnings. That is unusually candid language for a company that has spent years defending the deal. Combined with the US$1.5 billion already taken at the FY26 half year, total Vifor-related write-downs are now meaningful relative to the original price.
The impairment itself is non-cash. What matters is the admission embedded in it. The board is signalling that capital allocation discipline is back on the agenda, with a stated target of 1.5 to 2.0 times net debt to EBITDA.
The core plasma business is still working
Strip out the noise and CSL Behring’s underlying franchise looks healthier than the guidance cut suggests. US immunoglobulin end-customer demand is still growing at mid to high single digits, with Privigen share rising from 19% in 2023 to 21% in 2025, and Hizentra moving from 55% to 57% over the same period. The US$300 million revenue hit is an inventory unwind, not a demand problem.
China albumin tells a similar story. CSL has added more than 100 hospitals and is gaining share, but the market price has fallen. Volume is stable, value is down.
Seqirus is also expected to perform moderately better than previously guided, and the influenza vaccines business is being operationally separated from 1 July. Investors who can look past the reset will note that the operating engine is intact.
Naylor is positioning the next CEO, not himself
Worth noting, Naylor has been explicit that his job is to position the business and the next CEO for success. The global CEO search is progressing, and Naylor will move to a non-executive director role once the appointment lands.
The skeptical read is that taking the impairment now, while the seat is technically vacant, allows the incoming CEO to start with a cleaner base and lower expectations. That is a well-worn playbook, and it usually works over a 12 to 18 month horizon, provided the underlying business cooperates.
The risk is that today’s cut is not the last one. Management has flagged that the impairment numbers remain subject to further analysis, audit and board approval, with the next update at the 18 August full-year result.
The Investors Takeaway for CSL Limited
The setup from here is reasonably clean. Guidance has been reset, Vifor has been written down, and a new CEO is on the way. For long-term holders who have watched CSL drift sideways since the Vifor deal, today reads more like a reset than a structural break. We cover more ASX healthcare resets like this at stocksdownunder.
The 18 August full-year result is when investors will see whether the H2 Behring revenue acceleration management is promising actually shows up, and whether the impairment number is final. Until then, CSL becomes a story about confidence in the new playbook rather than the old one.
